- First site in Health Care business to achieve carbon neutrality in Scope 1 and 2 emissions
- Switch to biogas from local supplier
- Goal of carbon neutrality in Scope 1 and 2 emissions for all Health Care sites by 2030
Evonik’s production site in Ham in northern France has reduced its direct (Scope 1) and indirect (Scope 2) greenhouse gas emissions to zero. This is the first site from the Health Care business at Evonik to go carbon neutral and underscores the business’s commitment to its goal of becoming carbon neutral in Scope 1 and 2 emissions by 2030.
Evonik Health Care is part of the company’s life sciences division, Nutrition & Care. Guided by a vision that puts sustainability at its core, the division has defined concrete objectives and action plans to achieve carbon neutrality. In the case of the site in Ham, the next phase includes measures and activities to significantly reduce indirect CO2 emissions from supply chains, such as raw materials (Scope 3).
“With this achievement we have taken an important step in our decarbonisation journey. By reducing our footprint, we are providing our customers with the sustainable products they need, while helping to create a healthier, cleaner future for all,” said Thomas Riermeier, head of Evonik’s Health Care business.
Evonik Rexim SAS in Ham, France has been using green electricity since the beginning of 2022. In May this year, the site switched from using natural gas to biogas (biomethane produced from agricultural waste) supplied by local energy company ENGIE. With this new supplier, the site benefits from the well-developed biogas network in northern France.
Evonik’s Health Care business line is a global innovation hub to the world’s leading pharmaceutical, nutraceutical and medical device companies. The production site in Ham manufactures amino acids and peptides for application in cell culture and parenteral nutrition. Approximately 230 employees work at the site, which has been in operation for more than 70 years.
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €18.5 billion and an operating profit (adjusted EBITDA) of €2.49 billion in 2022. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. About 34,000 employees work together for a common purpose: We want to improve life today and tomorrow.
About Nutrition & Care
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €4.24 billion in 2022 with about 5,700 employees.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.